This role serves as the subject matter expert on access and reimbursement for Korlym, Mifepristone AG, and Relacorilant, supporting healthcare providers (HCPs), field sales teams, specialty pharmacies (SPs), and our patient support HUB to resolve barriers to patient access. With advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease, Corcept is unlocking the power of cortisol modulation to help address some of the most devastating diseases patients face today.